Here are the Form 4 insider transactions from Vor Biopharma Inc. (VOR) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow VOR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VOR filings page.
Vor Biopharma Inc. Chief Medical Officer Jeremy Brett Sokolove had 1,917 shares withheld by the company on November 2, 2026, at $19.25 per share, to satisfy tax withholding obligations tied to vesting of restricted stock units granted November 1, 2025. He directly held 25,983 shares after the transaction.
Vor Biopharma Inc. (VOR) reported that an option granted to Andrew Levin under its non-employee director compensation policy, and held for the benefit of RA Capital Healthcare Fund, L.P., was exercised on October 2, 2026. The exercise covered 500 options at an exercise price of $12.80 per share, yielding 500 common shares. Levin is obligated to turn the shares over to the Fund’s adviser, RA Capital Management, L.P., to offset advisory fees owed by the Fund; the reported option position after exercise was 0 shares.
Vor Biopharma Inc. (VOR) reported that entities associated with RA Capital Management, L.P., a ten percent owner, effected an exercise of a stock option for 1,500 shares of Common Stock on August 24, 2026. The option, with an exercise price of $3.736 per share, was immediately exercisable and is now fully exercised with 0 options remaining for this grant.
The option had been granted to non-employee director Joshua Resnick under Vor Biopharma’s director compensation policy, but under his arrangement with RA Capital, any stock received upon exercise is turned over to RA Capital Management, offsetting advisory fees owed by RA Capital Healthcare Fund, L.P. The Adviser, its general partner, the Fund, and individuals Peter Kolchinsky and Rajeev Shah all disclaim beneficial ownership of the option and underlying shares except for any pecuniary interest. The exercise terms reflect a 1-for-20 reverse stock split effected by Vor Biopharma on September 18, 2025.
RA Capital Healthcare Fund LP, an affiliate of RA Capital Management and a 10% owner of Vor Biopharma, exercised pre-funded warrants for 2,100,000 common shares at $0.002 per share. The exercise was cashless, so 213 shares valued at $19.75 were withheld to pay the exercise price and 2,099,787 shares were issued to the Fund. Following the transaction, the Fund continued to hold 7,900,000 pre-funded warrants, which are immediately exercisable with no expiration but subject to a 19.99% beneficial ownership cap. RA Capital Management, its general partner, and Dr. Peter Kolchinsky and Mr. Rajeev Shah disclaim beneficial ownership beyond their pecuniary interest, and the securities are held directly by the Fund.
Vor Biopharma director David Zaccardelli received a new stock option grant. The award covers 42,658 options to buy Vor Biopharma common stock at an exercise price of $20.10 per share and expires on July 6, 2036. These options will vest in 36 equal monthly installments beginning on August 7, 2026, contingent on his continued service with the company.
Vor Biopharma Inc. reported a Form 4 showing a stock option grant related to Dr. Andrew Levin, connected with RA Capital. The option covers 57,162 shares of Vor Biopharma common stock at an exercise price of $14.09 per share, expiring on June 10, 2036. One thirty-sixth of the option vests on July 11, 2026 and then monthly, as long as Dr. Levin continues in service. Under his arrangement with the adviser, the option is held for the benefit of RA Capital Healthcare Fund, and the reporting persons disclaim beneficial ownership except for any pecuniary interest.
Vor Biopharma Inc. director Michel Detheux received a grant of stock options covering 57,162 shares of common stock. The options have an exercise price of $14.09 per share and expire on June 10, 2036. These are compensation-related awards, not open-market purchases.
One thirty-sixth of the option grant will vest and become exercisable on July 11, 2026, with additional installments vesting monthly thereafter, conditioned on Detheux’s continued service. Following this award, he holds options for 57,162 shares directly according to this filing.
Vor Biopharma Inc. director Fouad Namouni received a grant of stock options covering 56,549 shares of common stock. The options have an exercise price of $14.0900 per share and expire on June 10, 2036. One thirty-sixth of the options will vest and become exercisable on July 11, 2026, with additional portions vesting monthly thereafter, contingent on his continued service. Following this grant, he holds 56,549 stock options directly.
Vor Biopharma director Wouter Joustra received a stock option grant covering 57,162 shares of common stock. The option has an exercise price of $14.09 per share and expires on June 10, 2036. One thirty-sixth of the award vests monthly starting July 11, 2026, contingent on continued service. Following this compensation-related grant, Joustra holds 57,162 options directly and there were no open-market buys or sales reported.
Vor Biopharma Inc. director Erez Kalir received a grant of stock options covering 57,162 shares of common stock. The options have an exercise price of $14.09 per share and expire on June 10, 2036. One thirty-sixth of the options vest on July 11, 2026 and then monthly thereafter, subject to continued service, so the award vests over three years. Following this grant, the reported derivative holdings from this award total 57,162 options held directly.
Vor Biopharma Inc. reported that director Alexander Cumbo received a grant of stock options on Common Stock as part of his compensation. The award covers 56,345 options with an exercise price of $14.09 per share, all held directly.
These options expire on June 10, 2036 and relate to 56,345 underlying shares of Common Stock. According to the vesting terms, one thirty-sixth of the options will vest and become exercisable on July 11, 2026 and each month thereafter, conditioned on Mr. Cumbo’s continued service through each vesting date.
Vor Biopharma director Daniella Beckman received a grant of 53,283 stock options to buy Vor Biopharma common stock at an exercise price of $14.09 per share. These options were awarded as compensation and are held directly.
According to the vesting schedule, one thirty-sixth of the options will vest and become exercisable on July 11, 2026, with additional installments vesting monthly thereafter, as long as she continues to serve the company. After this grant, she holds stock options covering 53,283 underlying shares, which will expire on June 10, 2036 if not exercised.
Vor Biopharma Inc. reported that director Andrew David Levin was granted a stock option covering 57,162 shares of common stock at an exercise price of $14.09 per share. The option expires on June 10, 2036 and is a compensation-related award.
One thirty-sixth of the option vests and becomes exercisable each month starting on July 11, 2026, subject to his continued service. Under an arrangement with RA Capital Management, L.P., Levin holds this option for the benefit of the RA Capital Healthcare Fund, L.P. and is obligated to turn over any net cash or stock received, and he therefore disclaims beneficial ownership of the option and underlying shares.
Vor Biopharma Inc. reported an open‑market sale of its common stock by entities associated with RA Capital. On April 22, 2026, RA Capital Healthcare Fund LP sold 165,150 shares of Vor Biopharma common stock at a weighted average price of $15.77, through multiple trades between $15.75 and $15.85. After these transactions, the fund continued to hold 2,402,095 shares indirectly reported. RA Capital Management, L.P., its general partner RA Capital Management GP, LLC, and managing members Dr. Peter Kolchinsky and Mr. Rajeev Shah each disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests.
Vor Biopharma Inc. reported that an investment vehicle associated with RA Capital executed open-market sales of its Common Stock. On April 17, 2026, the RA Capital Healthcare Fund LP sold 458,411 shares at a weighted average price of $16.28 per share, in multiple trades between $15.95 and $16.85.
On April 20, 2026, the Fund sold an additional 171,963 shares at a weighted average price of $15.77 per share, with individual trades between $15.75 and $16.00. Following these transactions, the Fund held 2,567,245 shares of Vor Biopharma common stock indirectly, and RA Capital Management, its general partner and principals disclaim beneficial ownership beyond their pecuniary interests.
Vor Biopharma Inc. insider entities associated with RA Capital reported open-market sales of an aggregate 737,989 shares of Common Stock over three days at weighted average prices around $16 per share. The shares are held directly by RA Capital Healthcare Fund, L.P., for which RA Capital Management, L.P. is investment manager.
After these transactions, the reporting entities continue to hold 3,197,619 shares of Vor Biopharma common stock indirectly. RA Capital Management, its general partner, and managing members Dr. Peter Kolchinsky and Mr. Rajeev Shah each disclaim beneficial ownership of the reported securities except to the extent of any pecuniary interest.
RA Capital Healthcare Fund LP, an entity associated with RA Capital Management, reported open-market sales of Vor Biopharma common stock over three days. The filings show indirect sales totaling 620,133 shares of Common Stock on April 8–10, 2026, at weighted average prices between $15.75 and $16.98 per share, executed in multiple trades within those ranges. After these transactions, the reporting group indicates indirect ownership of 3,935,608 shares. The Adviser, its general partner, the Fund, and individuals Peter Kolchinsky and Rajeev Shah each disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest.
RA Capital Healthcare Fund LP, through RA Capital Management, reported open-market sales of Vor Biopharma common stock. On April 2 and April 6, the Fund sold a total of 849,257 shares at prices ranging from $16.25 to $19.09 per share, using weighted-average pricing for each trade block.
After these transactions, the Fund indirectly held 4,555,741 Vor Biopharma shares, with RA Capital Management and related principals disclaiming beneficial ownership beyond their pecuniary interests. All reported holdings are described as being held directly by the Fund.
Vor Biopharma Inc. reported an insider equity update involving its officer serving as CFO. On December 5, 2025, the company’s compensation committee approved the cancellation of 694,137 restricted stock units, leaving the reporting person with no directly held common stock after the transaction.
On the same date, the CFO acquired an employee stock option covering 1,388,274 shares of common stock, expiring on December 4, 2035. The exercise price is $17.80 per share, or $8.18 per share if the option is exercised after a defined “Retention Period” that runs from December 5, 2025 through the earlier of December 5, 2027 or a qualifying change in control during continuous service. One quarter of the option vests on July 1, 2026, with the rest vesting in equal monthly installments over three years, subject to continued service. Share counts reflect a 1-for-20 reverse stock split completed on September 18, 2025.